Pfizer Stock Faces Uncertainty Following CFO Departure and Clinical Miss

Pfizer's stock is under scrutiny after a CFO departure and a clinical trial miss, raising questions about the company's future valuation. Investors are evaluating whether to maintain their positions in the pharmaceutical giant.